Smith joins the accountancy firm from Astrazeneca, the pharmaceutical giant responsible for the Oxford Covid-19 vaccine.
With 30 years of accounting experience, Smith’s previous roles include being a board member and chief financial officer at Astrazeneca, overseeing multiple product launches and organisation realignment.
In his new role with HW Fisher, Smith will manage the team’s operation, with the goal of maximising royalty revenue and reducing supplier costs.
Rafi Saville, a partner at HW Fisher Forensic, said: “Our strategy is to attract and invest in talent. Bringing someone of Martin’s caliber and incredible experience from AstraZeneca is perhaps the boldest statement we could make to back up our stated aim.
“We are excited to introduce him to current and prospective clients, because having stood in their shoes, he speaks their language and understands their concerns and will be able to drive straight to what is required to help them with their business operations and challenges.”
Smith said: “I’m delighted to be joining HW Fisher during such an important time for the pharma industry.
“I look forward to adding my pharma and transformation experience globally across Europe, Asia and the US to HW Fisher’s track record in forensic accounting to help further develop its already significant royalty auditing business, as well as further expanding its commercial assurance and contract audit offering.”